Last Chance to Save:
- 00Days
- 00Hrs
- 00Mins
- 00Secs
Monday, March 16th, 2026 — Pre-Conference Workshops - EST/EDT (Eastern Daylight, GMT-4)
Identify upcoming legislative and regulatory changes most likely to impact patient support programs and access initiatives
Understand how policy changes are viewed differently by government, industry, and patient advocacy organizations
Develop strategies to anticipate and prepare for policy shifts before they disrupt patient access
- Mike Eging - Leadership Team, Rare Access Project
- Aaron Winn - Associate Professor, University of Chicago
- Melissa Horn, MPA - Director of State Legislative Affairs, Arthritis Foundation
- Ulrich Neumann - Director, Access & Policy Research, Johnson & Johnson
Understand how Medicare drug price negotiations reshape patient assistance program design and eligibility requirements
Leverage premium smoothing provisions to enhance affordability while maintaining program sustainability
Adapt patient support services to align with Part D benefit restructuring and out-of-pocket caps
- Corey Ford - Principal, Nuvera, an Inizio Engage Company
Distinguish between generative AI, machine learning and predictive analytics models and evaluate the unique benefits and challenges of each
Map specific AI technologies to common patient journey pain points, from enrollment to adherence support
Build a framework for assessing AI maturity and readiness within your organization's patient support infrastructure
Master the current FDA guidance and industry standards governing AI applications in patient support programs
Implement ethical frameworks that protect patient data while enabling personalized support experiences
Create governance structures that maintain human oversight while leveraging AI capabilities
Implement a strategic timeline for engaging market access, trade, patient services, field teams and pricing/contracting stakeholders at optimal pre-launch intervals
Develop effective distribution models through collaborative planning between commercial and trade colleagues
Create frameworks for assessing market and payer challenges that inform contracting strategies and access planning
- Jeffrey Vernice - Director, Patient Excellence, Boehringer Ingelheim Pharmaceuticals, Inc.
- Manishi Prasad - Vice President, Market Access and Government Affairs, Beam Therapeutics
- Kristen Reilly - Senior Director, Strategic Insights & Access Analytics, Azurity Pharmaceuticals
Design patient identification approaches that scale appropriately from the focused rare disease setting to broader specialty markets
Implement competitive positioning tactics that account for different stakeholder landscapes and treatment alternatives
Create resource allocation models that optimize investment across the different demands of rare and mainstream therapeutic areas
- Mary Lou Szekeres - Senior Director Market Access Strategy and Marketing, Geron Corporation
- Alex Ross - Senior Director, Trade & Channel, Avidity Biosciences
- Jeff Krol - Vice President, Managed Markets & Access Strategy, Apnimed, Inc.
- Ashar Hasan - CEO, Medmonk
Explore how the Big Beautiful Bill (BBB) and new administration priorities transforms the patient support landscape, requiring innovative approaches to ensure continued access
Develop contingency plans for the revived Most Favored Nation drug pricing model and its impact on patient affordability
Master the changing Medicaid/Medicare landscape to serve dual-eligible populations
- Mike Eging - Leadership Team, Rare Access Project
- Alex Meixner - Vice President, State Policy, ALS Association
Explore the impact of GLOBE and GUARD on patient access and rare disease pipelines
Discuss the rapidly changing MFN policies and their effects on U.S. and global access
Examine strategies to address challenges and opportunities for patients
- Jennifer Snow - Founder, Apteka
Analyze case studies of AI implementations that significantly improved prior authorization success rates and adherence metrics
Evaluate integration approaches that connect AI capabilities with existing hub service platforms and workflows
Recognize warning signs of AI applications that create more problems than they solve
Witness compelling arguments from both AI advocates and critics on key implementation controversies
Develop strategies for addressing resistance to AI adoption while also legitimatizing concerns
Create a balanced perspective that acknowledges both AI's transformative potential and its practical limitations
Identify and evaluate the primary post-launch therapy barriers of access, affordability, copay burden and adherence across the patient journey
Design automated, coordinated workflows that align benefit verification, prior authorization and enrollment processes to reduce delays and administrative friction
Develop monitoring and governance frameworks that combine real-time affordability visibility with early risk detection to sustain long-term performance
- Dhiren Patel - Partner, Taurus Health
- Mark Beightol - Executive Vice President, Client Services, MedMonk
- Tina Valbh - Patient Advocate & Founder, Tina’s Warriors
Design patient support ecosystems that leverage uniquely US-market hub and specialty pharmacy capabilities
Create adaptable brand planning frameworks that accommodate different critical success factors across global markets
Implement competitive differentiation strategies tailored to market size, competition level, and treatment paradigms
**Open to pharmaceutical and biotech manufacturers only. Attendance is at the discretion of Informa and Inizio Engage.